V. Strugov

Impact of age and comorbidities on the efficacy of FC and FCR regimens in chronic lymphocytic leukemia

T. Andreeva, A. Zaritskey, V. Strugov, 2018, Annals of Hematology.

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.

R. Greil, J. Gribben, I. Flinn, 2019, The Lancet. Oncology.

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

E. Montserrat, J. Delgado, K. Stamatopoulos, 2020, Leukemia.

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial

R. Greil, J. Gribben, I. Flinn, 2022, Haematologica.

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib

K. Stamatopoulos, G. Gaidano, R. Rosenquist, 2023, Blood advances.

Orphan receptor ROR1 for detection of minimal residual disease in chronic lymphocytic leukemia

V. A. Bart, T. Vavilova, A. Zaritsky, 2020, Medical alphabet.

Еarly splenic response to ruxolitinib correlates with survival: a russian retrospective multicenter study in patients with myelofibrosis

G. Dimov, A. Zaritsky, E. Lomaia, 2023, Russian Journal for Personalized Medicine.